Suggested remit: To appraise the clinical and cost effectiveness of tepotinib within its marketing authorisation for treating adults with advanced non-small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutations.
 
Status In progress
Process STA 2018
ID number 3761

Provisional Schedule

Committee meeting 12 January 2022
Expected publication 23 March 2022

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck Serono Ltd (tepotinib)
Others Department of Health and Social care
  NHS England
  NHS Solihull CCG
  NHS South Lincolnshire CCG
  Welsh Government
Patient carer groups Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  Primary Care Respiratory Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine)
  Actavis UK (gemcitabine, paclitaxel, pemetrexed, vinorelbine)
  Bristol-Myers Squibb (nivolumab)
  Celgene (paclitaxel, nab-paclitaxel)
  Consilient Health Ltd (carboplatin, gemcitabine, vinorelbine)
  Dr Reddy’s Laboratories (docetaxel, pemetrexed)
  Eli Lilly (pemetrexed)
  Fresenius Kabi (docetaxel, paclitaxel)
  Fresenius Kabi Oncology (carboplatin, gemcitabine)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel)
  Medac GmbH (vinorelbine)
  Merck Sharp & Dohme (bevacizumab, pembrolizumab)
  Pfizer (bevacizumab, carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel)
  Pierre Fabre (vinorelbine)
  Roche (atezolizumab, bevacizumab)
  Sandoz (cisplatin)
  Sanofi (docetaxel)
  Seacross pharmaceuticals (docetaxel, paclitaxel, pemetrexed)
  Sun Pharma (carboplatin, gemcitabine)
  Teva UK (carboplatin, cisplatin, docetaxel, paclitaxel)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Pro-Cancer Research Fund

Timeline

Key events during the development of the guidance:

Date Update
11 May 2021 Invitation to participate
15 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-May 2021 when we will write to you about how you can get involved.
08 October 2020 - 05 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 March 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance